Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | CES1 | P23141 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25645644 | 0.88 | TSHR (0.63) | TSHRKMT2AMEN1NPC1MAPT | |
| SCHEMBL9196452 | 0.84 | HTT (0.71) | TSHRKMT2AMEN1NPC1MAPT | |
| SCHEMBL10958829 | 0.81 | TSHR (0.64) | TSHRKMT2AMEN1NPC1MAPT | |
| SCHEMBL11070861 | 0.79 | TSHR (0.57) | TSHRKMT2AMEN1NPC1MAPT | |
| SCHEMBL25645639 | 0.79 | L3MBTL1 (0.64) | TSHRKMT2AMEN1NPC1MAPT | |
| SCHEMBL8534214 | 0.79 | TSHR (0.57) | TSHRKMT2AMEN1NPC1MAPT | |
| SCHEMBL3693703 | 0.78 | TSHR (0.78) | TSHRKMT2AMEN1NPC1MAPT | |
| SCHEMBL10862020 | 0.78 | TSHR (0.55) | TSHRKMT2AMEN1NPC1MAPT | |
| SCHEMBL6201780 | 0.78 | LMNA (0.65) | TSHRKMT2AMEN1MAPTMAPK1 | |
| SCHEMBL9350244 | 0.77 | MAPT (0.53) | TSHRKMT2AMEN1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354453-B2 | Bupropion hydrobromide and therapeutic applications | VALEANT INTERNATIONAL BERMUDA (BM) | 2013-01-15 | — | — | US | disclosed |
| US-20100104639-A1 | BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2010-04-29 | — | — | US | disclosed |
| US-7671094-B2 | Bupropion hydrobromide and therapeutic applications | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2010-03-02 | — | — | US | disclosed |
| US-7649019-B2 | controlled release tablet of bupropion hydrobromide for reducing the ratio of the maximum/minimum plasma bupropion hydrobromide concentration (Cmax/Cmin) while maintaining bupropion plasma levels within the therapeutic window upon administration to a patient; more stable than buproin hcl | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2010-01-19 | — | — | US | disclosed |
| US-7645901-B2 | Crystal form; controlled release tablet of bupropion hydrobromide for reducing the ratio of the maximum/minimum plasma bupropion hydrobromide concentration (Cmax/Cmin) while maintaining bupropion plasma levels within the therapeutic window upon administration to a patient; more stable than buproin hcl | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2010-01-12 | — | — | US | disclosed |
| US-7645802-B2 | Controlled release, once daily formulation; reducing seizure side effects; antidepressant | BIOVAIL LABORATORIES INTERNATIONAL SRL. (BB) | 2010-01-12 | — | — | US | disclosed |
| US-7585897-B2 | Core comprising bupropion hydrobromide, binder, lubricant, and time-release coating surrounding core; storage stability | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2009-09-08 | — | — | US | disclosed |
| US-7579380-B2 | Microparticles having osmotic subcoat; extended release tablets; shelf life; hydrobromide form | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2009-08-25 | — | — | US | disclosed |
| US-7569610-B2 | Administering bupropion hydrobromide to treat seasonal affective, obsessive compulsive, post-traumatic stress, psychological, respiratory system, attention deficit/hyperactivity, sexual or sleep disorders; anxiolytic agents, antidepressants; neurpathic pain, fibromyalgia, viricides; headaches, obesity | BIOVAIL LABORATORIES INTERNATIONAL SRL (BB) | 2009-08-04 | — | — | US | disclosed |
| US-7563823-B2 | Controlled release matrix | BIOVAIL LABORATORIES INTERNATIONAL SRL. (BB) | 2009-07-21 | — | — | US | disclosed |
| US-20080274181-A1 | BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS | BIOAVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2008-11-06 | — | — | US | disclosed |
| US-20080081068-A1 | Core comprising bupropion hydrobromide, binder, lubricant, and time-release coating surrounding core; storage stability | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2008-04-03 | — | — | US | disclosed |
| US-20080075774-A1 | BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS | BIOAVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2008-03-27 | — | — | US | disclosed |
| US-20080057120-A1 | controlled release tablet of bupropion hydrobromide for reducing the ratio of the maximum/minimum plasma bupropion hydrobromide concentration (Cmax/Cmin) while maintaining bupropion plasma levels within the therapeutic window upon administration to a patient; more stable than buproin hcl | BIOAVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2008-03-06 | — | — | US | disclosed |
| US-20080038345-A1 | Microparticles having osmotic subcoat; extended release tablets; shelf life; hydrobromide form | BIOAVAIL LABORATORIES (BB) | 2008-02-14 | — | — | US | disclosed |
| US-20080033044-A1 | Crystal form; controlled release tablet of bupropion hydrobromide for reducing the ratio of the maximum/minimum plasma bupropion hydrobromide concentration (Cmax/Cmin) while maintaining bupropion plasma levels within the therapeutic window upon administration to a patient; more stable than buproin hcl | BIOAVAIL LABORATORIES (BB) | 2008-02-07 | — | — | US | disclosed |
| US-20070276047-A1 | Administering bupropion hydrobromide to treat seasonal affective, obsessive compulsive, post-traumatic stress, psychological, respiratory system, attention deficit/hyperactivity, sexual or sleep disorders; anxiolytic agents, antidepressants; neurpathic pain, fibromyalgia, viricides; headaches, obesity | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2007-11-29 | — | — | US | disclosed |
| US-20070269516-A1 | Controlled release matrix | BIOAVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2007-11-22 | — | — | US | disclosed |
| US-7241805-B2 | For therapy of depressive condition | BIOVAIL LABORATORIES, INC. (CA) | 2007-07-10 | — | — | US | disclosed |
| US-20070027213-A1 | For therapy of depressive condition | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (CA) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081068-A1 | Core comprising bupropion hydrobromide, binder, lubricant, and time-release coating surrounding core; storage stability | SLC6A2, SLC6A3, HTR5A | TSHR 2980/4885KMT2A 1771/4885MEN1 3880/4885 |
| US-20070276047-A1 | Administering bupropion hydrobromide to treat seasonal affective, obsessive compulsive, post-traumatic stress, psychological, respiratory system, attention deficit/hyperactivity, sexual or sleep disorders; anxiolytic agents, antidepressants; neurpathic pain, fibromyalgia, viricides; headaches, obesity | HCRTR2, HCRTR1, SLC6A2 | TSHR 2155/4885KMT2A 3435/4885MEN1 4243/4885 |
| US-20080057120-A1 | controlled release tablet of bupropion hydrobromide for reducing the ratio of the maximum/minimum plasma bupropion hydrobromide concentration (Cmax/Cmin) while maintaining bupropion plasma levels within the therapeutic window upon administration to a patient; more stable than buproin hcl | SLC6A2, BDNF, SLC6A11 | TSHR 2219/4885KMT2A 2411/4885MEN1 413/4885 |
| US-20080033044-A1 | Crystal form; controlled release tablet of bupropion hydrobromide for reducing the ratio of the maximum/minimum plasma bupropion hydrobromide concentration (Cmax/Cmin) while maintaining bupropion plasma levels within the therapeutic window upon administration to a patient; more stable than buproin hcl | BDNF, MME, SLC6A11 | TSHR 2012/4885KMT2A 3338/4885MEN1 414/4885 |
| US-20070027213-A1 | For therapy of depressive condition | SLC6A2, SLC6A4, HTR5A | TSHR 1384/4885KMT2A 1485/4885MEN1 3892/4885 |
| US-20080075774-A1 | BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS | GABBR1, SLC6A2, GABBR2 | TSHR 1150/4885KMT2A 2830/4885MEN1 2766/4885 |
| US-20070269516-A1 | Controlled release matrix | SLC6A2, SLC6A11, SLC6A1 | TSHR 1691/4885KMT2A 1801/4885MEN1 3180/4885 |
| US-20080274181-A1 | BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS | GABBR1, SLC6A2, GABBR2 | TSHR 1150/4885KMT2A 2830/4885MEN1 2766/4885 |
| US-20100104639-A1 | BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS | GABBR1, SLC6A2, GABBR2 | TSHR 1150/4885KMT2A 2830/4885MEN1 2766/4885 |
| US-20080038345-A1 | Microparticles having osmotic subcoat; extended release tablets; shelf life; hydrobromide form | SLC6A2, SLC6A4, SLC6A3 | TSHR 2832/4885KMT2A 681/4885MEN1 3407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.